MARKETING ANALYSIS OF ADEMETHIONINE ІN THE PHARMACEUTICAL MARKET OF UKRAINE
DOI:
https://doi.org/10.30888/2663-5712.2023-18-02-055Keywords:
Ademethionine, hepatoprotector, marketing analysis, assortmentAbstract
The article presents the results of the marketing analysis of Аdemethionine presented on the pharmaceutical market of Ukraine. A review of literature sources on preclinical and clinical studies was conducted, the main areas of application of the drug wereMetrics
References
Dundar, H. Z., Yilmazlar, T. Management of hepatorenal syndrome. World journal of Nephrology. 2015. №6; 4(2). Р.277-286. doi:10.5527/wjn.v4.i2.277.
Acevedo, J. G., Cramp, M. E. Hepatorenal syndrome: Update on diagnosis and therapy. World journal of Hepatology. 2017. №28; 9(6). Р.293-299. doi: 10.4254/wjh.v9.i6.293.
Radchenko, O.M. Vybir hepatoprotektora dlia likuvannia urazhen pechinky. Health-ua.com Medychna hazeta. 2020. № 1 (470) [Elektronnyi resurs].
Tereshchenko, L.O. Efektyvnist Heptralu u farmakolohichnii korektsii hlutationovoi redoks systemy v selezintsi oprominenykh shchuriv. Aktualni problemy transportnoi medytsyny. 2017. № 2 (48). S. 84−87.
Normatyvno dyrektyvni dokumenty MOZ Ukrainy. Heptral. [Elektronnyi resurs]. Rezhym dostupu: http://mozdocs.kiev.ua/likiview.php?id=12025).
S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis / T. Guo et al. PLoS One. 2015. Vol. 10, № 3. e0122124. doi: 10.1371/journal.pone.0122124.
Lu, Sh. C., Mato, J. M. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev. 2012. Vol. 92, № 4. P. 1515–1542. doi: 10.1152/physrev.00047.2011.
Cantoni G. L. The nature of the active methyl donor formed enzymatically from l-methionine and adenosine triphosphate.J. Am. Chem. Soc. 1952. Vol. 74, № 11. P. 2942-294. doi: 10.1021/ja01131a519.
«Rokovaia tsepochka» y ademetyonyn / N. B. Huberhryts y dr. Suchasna hastroenterolohiia. 2014. № 4. S. 106–120.
Iurev, K. L. Ademetyonyn pry bolezniakh pecheny. Dokazatelnoe dose. Ukraynskyi medytsynskyi zhurnal. 2011. № 3. S. 63–69.
Tatarenko O. Heptral kak hepatoprotektor vыbora v terapyy patsyentov s zabolevanyiamy pecheny. Hastroэnterolohyia y hepatolohyia: mater. konf. 13 15 maia 2011 h., Ytalyia. Zdorovia Ukrainy. 2011. № 10–15 (268–269). S. 10–12.
S-Adenosylmethionine affects cell cycle pathways and suppresses proliferation in Liver Cells / Yan l. et al. J Cancer. 2019. Vol. 10, № 18. P. 4368–4379. doi: 10.7150/jca.25422.
Ermolova, Yu. V. Heptral pry porazhenyiakh pecheny. Ukrainskyi medychnyi chasopys. 2011. № 4 (84). S. 61–63.
Chernova V. M., Kushnir I. E. Patohenetychni mekhanizmy i terapevtychni aspekty vnutrishnopechinkovoho kholestazu pry khronichnykh zakhvoriuvanniakh pechinky. Suchasna hastroenterolohiia. 2013. № 6 (74). S. 100–107.
Burdak, K. S., Yarnykh T. H., Borshchevska M. I. Hepatoprotektory v likuvanni zakhvoriuvan pechinky: porivnialna kharakterystyka. Suchasni dosiahnennia farmatsevtychnoi tekhnolohii ta biotekhnolohii: zb. nauk. prats za mat. V nauk.-prakt. internet-konf. z mizhn.uchastiu. m. Kharkiv, 18 lyst. 2016 r. Kharkiv, 2016. S. 734–738.
Clinical efficacy of S-adenosylmethionine in patients with non-alcoholic steatohepatitis and chronic kidney disease І-ІІ stage / A. Antoniv et al. Georgian Med News. 2017. Vol. 273. P. 31–36.
S-adenosyl-L-methionine modifies antioxidant-enzymes, glutathione-biosynthesis and methionine adenosyl-transferases-1/2 in hepatitis C virus-expressing cells / S. A. Lozano-Sepulveda et al. World J Gastroenterol. 2016. Vol. 22, № 14. P. 3746−3757. doi: 10.3748/wjg.v23.i40.7343
Karas K. N. S-Adenosyl methionine in the therapy of depression and other psychiatric disorders. Drug Dev Res. 2016. Vol. 77, № 7. P. 346−356. doi: 10.1002/ddr.21345.
S-Adenosylmethionine (SAMe) for neuropsychiatric disorders: a clinician-oriented review of research.; as work group of the american psychiatric association council on research / A. Sharma et al. J Clin Psychiatry. 2017. Vol. 78, № 6. P. 656–667. doi: 10.4088/JCP.16r11113.
Evaluation of antiepileptic effect of S-adenosyl methionine and its role in memory impairment in pentylenetetrazole-induced kindling model in rats / R. M. Dhediya et. al. Epilepsy Behav. 2016. Vol. 61. P. 153–157. doi: 10.1016/j.yebeh.2016.05.024.
Sikora M., Pham K., Ufnal M. Hypotensive effect of S-adenosyl-L-methionine in hypertensive rats is reduced by autonomic ganglia and KATP channel blockers. Amino Acids. 2016. Vol. 48, № 7. P. 1581–1590. doi: 10.1007/s00726-016-2213-4.
S-adenosylmethionine reduces airway inflammation and fibrosis in a murine model of chronic severe asthma via suppression of oxidative stress / S. Y. Yoon et al. Exp Mol Med. 2016. Vol. 48, № 6: e236. doi: 10.1038 / emm.2016.35.
Drachuk V., Zamorskii I., Shchudrova T., Kopchuk T., Goroshko O. Efficacy of ademetionine in acute kidney injury of different genesis. Pharmacology OnLine, 2020;2:92-99. ISSN: 1827-8620
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
